NIOX Group PLC
82C
Company Profile
Business description
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.
Contact
1 Robert Robinson Avenue
The Magdalen Centre
The Oxford Science Park
OxfordOX4 4GA
GBRT: +44 3303309356
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
84
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,716.80 | 22.20 | 0.26% |
| CAC 40 | 7,981.07 | 27.30 | 0.34% |
| DAX 40 | 23,278.85 | 115.93 | 0.50% |
| Dow JONES (US) | 45,752.26 | 386.51 | -0.84% |
| FTSE 100 | 9,527.65 | 20.24 | 0.21% |
| HKSE | 25,835.57 | 4.92 | 0.02% |
| NASDAQ | 22,078.05 | 486.18 | -2.15% |
| Nikkei 225 | 48,790.24 | 1,033.70 | -2.07% |
| NZX 50 Index | 13,350.58 | 88.82 | -0.66% |
| S&P 500 | 6,538.76 | 103.40 | -1.56% |
| S&P/ASX 200 | 8,443.30 | 26.80 | 0.32% |
| SSE Composite Index | 3,930.55 | 0.50 | -0.01% |